17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Critically ill patients are at high risk for development of life-threatening infection leading to sepsis and multiple organ failure. Adequate antimicrobial therapy is pivotal for optimizing the chances of survival. However, efficient dosing is problematic because pathophysiological changes associated with critical illness impact on pharmacokinetics of mainly hydrophilic antimicrobials. Concentrations of hydrophilic antimicrobials may be increased because of decreased renal clearance due to acute kidney injury. Alternatively, antimicrobial concentrations may be decreased because of increased volume of distribution and augmented renal clearance provoked by systemic inflammatory response syndrome, capillary leak, decreased protein binding and administration of intravenous fluids and inotropes. Often multiple conditions that may influence pharmacokinetics are present at the same time thereby excessively complicating the prediction of adequate concentrations. In general, conditions leading to underdosing are predominant. Yet, since prediction of serum concentrations remains difficult, therapeutic drug monitoring for individual fine-tuning of antimicrobial therapy seems the way forward.

          Related collections

          Author and article information

          Journal
          Adv. Drug Deliv. Rev.
          Advanced drug delivery reviews
          1872-8294
          0169-409X
          Nov 20 2014
          : 77
          Affiliations
          [1 ] Dept. of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium; The Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia. Electronic address: stijn.blot@UGent.be.
          [2 ] Institute of Clinical Pharmacology, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Italy; Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy. Electronic address: pea.federico@aoud.sanita.fvg.it.
          [3 ] The Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia; Dept. of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Butterfield St, Herston QLD 4006, Australia. Electronic address: j.lipman@uq.edu.au.
          Article
          S0169-409X(14)00147-1
          10.1016/j.addr.2014.07.006
          25038549
          806014ff-526f-42b9-9e76-59f8ccbb130d
          Copyright © 2014. Published by Elsevier B.V.
          History

          Acute kidney injury,Antimicrobial agents,Hepatic failure,Intensive care unit,Organ failure,Pharmacodynamics,Pharmacokinetics,Sepsis

          Comments

          Comment on this article